Sponsored by: 

Sponsored by: 

Sponsored by 

In February 2021, U.S. FDA announced the agency “approved, cleared, or authorized a record high of 132 novel medical devices in 2020, surpassing the 40-year high mark we set in 2018 and capping off 10 years of progress.” In a remarkable display of agility, medtech affairs and commercial teams, including KOLs, and regulatory bodies found a way to advance and deliver innovations in a time of unprecedented disruption. This achievement was made possible in part by accelerating adoption of virtual engagement tools that kept medical affairs, commercial teams, customers and patients engaged. 

As teams adapt to a post-Covid world, how can virtual engagement increase its value provision to medical affairs and commercial teams further accelerating commercialization? What strategies and tools should leadership of life science companies embrace as a hybrid approach to medical affairs and commercial programs becomes the norm and starts to mature?

Speakers:

• Dickson Bueno, Creative Services Director, Within3
• Lee Burnes, VP, Global R&D, Avanos Medical
• Paul Snyder, VP Healthcare, Write2Market (moderator)

Sponsored by: 

Sponsored by: 

During the morning session, Silicon Valley Bank will present data on new investment trends in the southeast, post covid. The investor panel will discuss the SVB data and determine if it matches up with what the investors are seeing “on the ground.” In addition, the investors will review other changes not addressed by SVB, including geographic distribution (coming in and going out of the southeast) of funds, has covid affected diversity investment, and general discussion on investment trends.

Panelists

• Todd Creech, Partner, HealthQuest Capital
• James Ramey, Managing Director, VTC Ventures

Sponsored by: 

Sponsored by: 

The COVID virus has demonstrated the incredible power of molecular diagnostics, and global informatics, to track constantly-mutating infectious diseases, and to accelerate development of a new arsenal of vaccines and therapeutics.   Information technology and massive data storage capability make it possible, but did not supplant the need to educate populations about how to prevent the spread of disease, encourage vaccines, and prepare for the next pandemic.

The COVID virus global crisis accelerated the development of capabilities and capacity to test at a molecular level for a wide range of healthcare conditions:  genetic disorders, cancer diagnostics and monitoring, disease diagnosis, prognosis and progression, response to therapeutics and predisposition to diseases.

From 23andMe to Castle Biosciences, new companies have emerged to harness these molecular genetic platforms to provide personalized solutions as well as COVID-like population-wide sentinel operations to foster better health.

This panel will discuss some of the trends, innovators, and future directions for investments that help bring about the long awaited promised of “personalized medicine.”

Sponsored by: 

Sponsored by: 

• During our networking sessions, we will utilize the capabilities of Zoom to break attendees into rooms for networking.

Sponsored by: 

Sponsored by: 

Kim serves as the organizational integrator at Mammoth Fund with a strong focus toward aligning the interests of the investment adviser, fund manager, investors, and portfolio company founders.

Kim creates efficient processes to conceptualize and develop compelling solutions for the problems facing businesses and their customers. She leverages her deep know-how to help portfolio companies integrate data and technology to help them deliver proprietary experiences to their customers. Kim also leverages her operational expertise to allow Mammoth lean operations, better aligning our interests with Fund Members.

Kim began her career in the nonprofit world and moved to a publicly traded company in 2005 where she coordinated joint marketing across a global sales team. In 2009, Kim opened a boutique design firm and began building technology and experiences for concierge medicine and wealth management firms.

In 2015, Kim co-founded Mineral Interactive. Kim led operations and strategy for the firm, creating marketing campaigns and digital products for many of independent wealth management’s leading fintech and wealth management brands. Kim’s work won multiple awards and eight of her portfolio companies went on to successful acquisitions and recapitalizations.

Kim achieved a strategic exit when Mineral was acquired by Carson Group in 2018, where Kim went on to lead marketing and client
experience design. Her work there included an enterprise rebrand and ensured the design and delivery of a complete end to end digital experience across 100+ national offices and 30,000+ retail investors.

Kim graduated summa cum laude from Grace University in Omaha (BA). She grew up around the world through her family’s various stops as part of the assignments with the United States Air Force including Germany, Washington DC, Hawaii and Omaha.

Sponsored by: 

Sponsored by: 

Sponsored by: 

Expect the best hospitality South Carolina has to offer with this add-on dinner experience on the beach at Wild Dunes. More details coming soon. 

Sponsored by: 

Sponsored By: 

mRNA has become a widely-known term after Moderna and Pfizer developed vaccines using the technology, but there is much more potential than that. This panel will cover the background on how the vaccines were created so quickly using MRNA and examine the potential of the technology in the future.

Sponsored by: 

Sponsored By: 

• Sponsored By: 

Sean Slovenski, CEO of BioIQ

Sean Slovenski is recognized as a healthcare industry innovator with a 30-year history of success. Slovenski is a proven senior executive and entrepreneur with an established track record in small, medium, and large-scale businesses.

Slovenski started his career by helping to build and then lead one of the nation’s first large-scale wellness efforts for Fortune 500 clientele. Envisioning the widespread usage of the Internet, Sean pioneered the development and delivery of wellness coaching online by inventing the first-of-its kind personal coaching product, MyHealthCoach.com. This effort led to being a co-founder and the CEO of the industry leading coaching company Hummingbird Coaching Services. Hummingbird was acquired by Humana, Inc. in July 2010.

Slovenski also adds to his credit the development and operations for two of the largest health system based Integrative Medicine and Wellness centers in the US, The Mercy Centers for Health & Wellness located in Cincinnati, Ohio as well as being the CEO of the international joint venture between Humana and Discovery Health of South Africa to create one of the largest and most proven wellness incentive companies in the industry.

Slovenski served as the CEO of Care Innovations, an Intel-GE joint venture in the telehealth and remote patient monitoring space.

Getting back to his wellness roots, Slovenski then took on reinventing the industry-leading population health company as the President of Population Health at Healthways, which Slovenski sold to ShareCare In 2016.

Most recently Slovenski served as the SVP and president of Walmart Health and Wellness. This business serves nearly half of all Americans each year through its 4,700 pharmacies, 2,800 optical centers, and the newly launched multi-disciplinary healthcare clinics known as the “Supercenters for Healthcare.”

Slovenski has the honor of being named Healthcare Leader of the Year by the US Chamber of Commerce in 2015 and 2019 as the 7th most influential person in healthcare out of the top 100 by Modern Health Magazine.

Slovenski resides in Cincinnati with his wife and daughter.

Sponsored by: 

Sponsored by: 

This panel will review the M&A and finance markets to determine what primary attributes are being valued in the market. From this data, the panel will discuss what you need to know to use AI to your advantage: AWS, consultancy, build vs buy, data management + engineering, building teams, choosing the right use cases, POCs, etc.

Sponsored by: 

Sponsored by: 

The Smart Money in Life Science Investing is Smart Everywhere, In Every Phase Including the Supply Chain and Manufacturing.

The Pandemic taught us that “just in time” and “lean” processes are easily and thoroughly disrupted when multiple environmental changes take place. 

If a product or technology involves novelty or materials and components critical to the product but not easily acquired or produced, that has the potential to extend development timelines, delay manufacturing transfer, time to market and ultimately adds risk that is ultimately unacceptable for investors. For example: distribution of Pfizer’s Covid vaccine demanded temperatures that required liquid oxygen for transport, it was a huge issue.

How do you reduce that risk? Make sure your team has the right expertise in manufacturing and supply chain then learn to play Judo with suppliers.

What attendees will learn

• Where are the supply chain and manufacturing landmines that generate risk investors may find unacceptable?
• How can investors mitigate those risks and when?
• At what point in the innovation process does manufacturing strategy need to enter the conversation and why?

Sponsored by: 

s interactive panel and discussion will cover the increasingly prevalent “virtual” work environment and how it may positively impact life science companies. Leveraging national and international resources is more viable now than ever, and can be a more efficient way to accelerate business growth. We will explore models and implementation strategies for remote and fractional executive management, as well as preclinical and clinical research.

Speakers

• Moderator: Russell Allen; BiotechExec
• Helena Cowley; Oxidien Pharma
• Mike Dial; Hatteras Venture Partners
• William Dull; Innovative Medicine Partners
• Marta New; Radyus Research

Sponsored by: 

You’ve come up with the idea, jumped through the legal paperwork, you have launched your company. Now what? This panel will review steps you need to take take your idea and make it into a company. The panelists will review topics such as?

• FDA & Reimbursement as it applies to your business plan
• Pitfalls to avoid,
• What to consider when or if you should select an accelerator
• How to manage and motivate your team  

Sponsored by: 

Sponsored by: 

Vivian S. Lee, M.D., Ph.D., M.B.A., is the author of The Long Fix: Solving America’s Health Care Crisis with Strategies that Work for Everyone (Norton). She is President of Health Platforms at Verily Life Sciences. A physician and health care executive, Lee also serves as a senior lecturer at Harvard Medical School.

Prior to joining Verily, Lee served as the Dean of the Medical School and CEO of the University of Utah Health Care, an integrated health system with a budget of $3.6 billion, including a 1400 member physician group and health insurance plan. During her tenure, she led University of Utah Health to recognition for its health care delivery system innovations that enable higher quality at lower costs and with higher patient satisfaction, and superior financial performance. In 2016, University of Utah was ranked first among all university hospitals in quality and safety (Vizient).  Dr. Lee previously was the inaugural Chief Scientific Officer of New York University’s Langone Medical Center.  

Elected to the National Academy of Medicine with over 200 peer-reviewed publications, Lee serves on the Board of Directors of the Commonwealth Fund, the Board of Trustees of Boston Children’s Hospital, and is also a director on the board of Zions Bancorporation, a publicly traded company.

Dr. Lee is a magna cum laude graduate of Harvard, received a D.Phil in medical engineering from Oxford University as a Rhodes Scholar, earned her M.D. with honors from Harvard Medical School, and her MBA from NYU. She was named by Modern Healthcare as one of the 50 Most Influential Clinical Executives in 2020.

Sponsored by: 

Sponsored by: